HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 02, February 2018 – Searching for the fountain of youth       » Chinese researchers cloned monkeys       » National Science and Technology Prizes       » Highlights from the State Natural Science Award       » Highlights from the State Technological Invention Award      
BIOBOARD - SINGAPORE & GERMANY
Breakthrough immunotherapy for Chronic Hepatitis B virus infection
Professor Antonio Bertoletti (Scientific Founder) & Dr Sarene Koh (Product Development Director) of Lion TCR Pte Ltd in Singapore collaborated with Professor Maura Dandri and Dr. Janine Kah of University Medical Center Hambourg and various Singapore & German institutions and published their findings on the effective control of chronic hepatitis B (CHB) infection with T cell immunotherapy in the July issue of the Journal of Clinical Investigation.

CHB has severe quantitative and functional defects in HBV-specific T cell response. Restoration of the HBV specific T cells are determinant to clear the virus of CHB. The team is the first to use mRNA transduction to engineer the transient HBV specific TCR-redirected T cells as a new therapeutic strategy against CHB. The research utilizes molecular biology techniques to modify the T cells of a patient. When infused back into the patient's body, the TCR redirected T lymphocytes find, recognize and inhibit or clear the hepatitis B virus in hepatocyte.

Hepatitis B is a viral infection of the liver that is a major global health problem. More than 250 million people are chronic hepatitis B (CHB) carriers and approximately 1 million people die every year from CHB-related diseases. There is an urgent need to design new strategies to eliminate and achieve functional cure of chronic HBV infection.

Various current therapies for HCC only inhibit the virus without clearance of the virus, patients continue to live under the danger of complications which many eventually die from.

This study, a collaborative effort between Duke-NUS, various prestigious Singapore & German institutions and Lion TCR, provides a potential solution to control the HBV infection, potentially complete clearance of HBV virus and possibly leading to a cure for CHB. The research uses proprietary technologies from Lion TCR Pte Ltd on TCR-T cell therapy invented by Prof Antonio Bertoletti.

Source: PRNewswire

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy